



**Proteome Sciences plc
("Proteome Sciences")**

PRESS RELEASE

US biomarker patent portfolio

22 August 2012 - The Directors of Proteome Sciences have been made aware of certain speculative and inappropriate comments regarding its US biomarker patent portfolio in light of two recent US court rulings on patent eligibility. We have reviewed the outcomes of the recent U.S. Supreme Court decision on *Mayo v. Prometheus* and U.S. Court of Appeals for the Federal Circuit decision on *Associated Molecular Pathology v. United States Patent and Trademark Office* with our US patent attorneys and we conclude that these decisions do not change the status of our issued and pending U.S. applications or impacted our granted U.S. patents which all continue to remain in good standing. The Company continues to fully prosecute and enforce its extensive biomarker patent estate in all territories, including the US to derive maximum value for our shareholders.

ENDS

For further information please contact:

Proteome Sciences plc

Christopher Pearce, Chief Executive Officer
Dr. Ian Pike, Chief Operating Officer
James Malthouse, Finance Director

Tel: +44 (0)1932 865065

Nominated Adviser

Cenkos

Stephen Keys/Camilla Hume

Tel: +44 (0)20 7397 8900

Public Relations

FTI Consulting

Ben Atwell / Simon Conway / Mo Noonan
Tel: +44 (0)20 7269 7116

IKON Associates

Adrian Shaw
Tel: +44 (0)1483 271291



Notes to Editors:

About Proteome Sciences

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. Its PS Biomarker Services™ uses isobaric and isotopic Tandem Mass Tag® (TMT®) workflows developed on the latest Orbitrap Velos and TSQ Vantage mass spectrometers to deliver rapid, robust and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt, Germany. By combining Selected Reaction Monitoring (SRM) and TMT® workflows highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in larger validation studies and can be transferred for immunoassay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or are already outlicensed. Proteome Sciences, based in Cobham, UK, with facilities in London and Frankfurt, delivers outsourced proteomics services and proprietary biomarkers/biomarker assays to pharmaceutical, biotechnology and diagnostics companies.

Visit: <http://www.proteomics.com>